Ben Clube, CEO of EnergyPathways, updates investors on progress at MESH. Watch the interview here.

Less Ads, More Data, More Tools Register for FREE
Sponsored Content
Sponsored Content

Pin to quick picksVerici Dx Regulatory News (VRCI)

Share Price Information for Verici Dx (VRCI)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 4.50
Bid: 4.25
Ask: 4.75
Change: -0.75 (-14.29%)
Spread: 0.50 (11.765%)
Open: 5.25
High: 5.25
Low: 4.125
Prev. Close: 5.25

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Medicare National Payment Rate Confirmation

8 Jan 2024 07:00

RNS Number : 8695Y
Verici Dx PLC
08 January 2024
 

Verici Dx plc

("Verici Dx" or the "Company") 

 

Medicare National Payment Rate for Tutivia? and Clarava? Effective as of January 1, 2024

CMS finalises gapfill median rate at $2,650 per test

Verici Dx plc (AIM: VRCI), a developer of advanced clinical diagnostics for organ transplant, announces that the Centers for Medicare & Medicaid Services ("CMS") released the Clinical Laboratory Fee Schedule ("CLFS") payment rate of $2,650 established through the "gapfill" process for both Tutivia? (CPT 0320U), its post-transplant test focused upon acute cellular rejection, and Clarava? (CPT 0319U), its pre-transplant prognosis test for the risk of early acute rejection. This rate is effective as of January 1, 2024.

Having a national payment rate established by CMS represents a step toward securing reimbursement for testing by Medicare, a national health insurance program in the US that covers 63.9 million patients. Gapfill pricing is a method used by CMS to establish a payment rate for clinical diagnostic laboratory tests when no comparable test is priced on the CLFS and involves setting the payment rate for the test at the median of rates established by local Medicare contractors.

Sara Barrington, Chief Executive Officer of Verici Dx, commented: "We are pleased that the pricing for both Tutivia? and Clarava? has been confirmed and finalised at the proposed rates. This is another important milestone in our strategy to develop and commercialise a complementary suite of ground-breaking products that offer end-to-end testing for kidney transplant patients and their clinicians."

 

Enquiries:

 

Verici Dx

www.vericidx.com

Sara Barrington, CEO 

Via Walbrook PR

Julian Baines, Chairman

 

 

 

Singer Capital Markets (Nominated Adviser & Broker)

Tel: 020 7496 3000

Aubrey Powell / Sam Butcher / Jalini Kalaravy

 

 

Walbrook PR Limited

Tel: 020 7933 8780 or vericidx@walbrookpr.com

Stephanie Cuthbert / Sam Allen

Mob: 07796 794 663 / 07502 558 258

 

 

About Verici Dx plc www.vericidx.com

Verici Dx is a developer of a complementary suite of leading-edge tests forming a kidney transplant platform for personalised patient and organ response risk to assist clinicians in medical management for improved patient outcomes. The underlying technology is based upon artificial intelligence assisted transcriptomic analysis to provide RNA signatures focused upon the immune response and other biological pathway signals critical for transplant prognosis of risk of injury, rejection and graft failure from pre-transplant to late stage. The Company also has a mission to accelerate the pace of innovation by research using the fully characterised data from the underlying technology, including through collaboration with medical device, biopharmaceutical and data science partners.

 

The foundational research was driven by a deep understanding of cell-mediated immunity and is enabled by access to expertly curated collaborative studies in highly informative cohorts in kidney transplant.

This information is provided by Reach, the non-regulatory press release distribution service of RNS, part of the London Stock Exchange. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
NRADBGDBCXGDGSR
Date   Source Headline
11th Oct 20247:00 amRNSUpdate on Local Coverage Determination and Trading
31st Jul 20247:00 amRNSLaunch of PTRA Assay using Verici Dx's technology
15th Jul 20247:00 amRNSHalf-year Report
11th Jul 20242:00 pmRNSNotice of Results and Business Update
1st Jul 20247:00 amRNSSignificant milestone re Thermo Fisher agreement
25th Jun 20241:27 pmRNSResult of AGM
18th Jun 20247:00 amRNSTransfer of urine samples to Thermo Fisher
31st May 20241:57 pmRNSNotice of AGM and posting of Annual Report
31st May 202410:00 amRNSLaunch of patient-focused educational tool
30th May 20247:00 amRNS2023 Annual Results
24th May 20247:00 amRNSNew data to be presented at ATC
27th Feb 20244:08 pmRNSHolding(s) in Company
22nd Feb 20247:00 amRNSHolding(s) in Company
21st Feb 20244:53 pmRNSHolding(s) in Company
21st Feb 20247:00 amRNSHolding(s) in Company
19th Feb 202412:35 pmRNSResult of General Meeting
14th Feb 20247:00 amRNSResult of Retail Offer
31st Jan 20247:00 amRNSVerici Dx announces new research initiative
26th Jan 202412:32 pmRNSPublication of Circular
25th Jan 202411:00 amRNSLaunch of Retail Offer
24th Jan 20246:11 pmRNSResult of Placing
24th Jan 202410:39 amRNSClose of Accelerated Bookbuild
24th Jan 20247:00 amRNSProposed Fundraising
8th Jan 20247:00 amRNSCAP accreditation
8th Jan 20247:00 amRNSMedicare National Payment Rate Confirmation
11th Dec 20237:00 amRNSTutiviaâ„¢ validation study published in Journal
29th Nov 20237:00 amRNSISO 27001 Information Security Certification
20th Nov 20237:00 amRNSInvestor Presentation
15th Nov 20237:00 amRNSCommercialisation agreement with Thermo Fisher
2nd Nov 20237:00 amRNSClaravaâ„¢ poster to be presented at ASN Kidney Week
29th Sep 20237:00 amRNSHalf-year Report
20th Jul 20237:00 amRNSCLIA Certificate of Compliance update
6th Jul 20237:00 amRNSInvestor Presentation
3rd Jul 20237:00 amRNSSuccessful clinical validation of Clarava™
29th Jun 20234:57 pmRNSResult of AGM
6th Jun 20237:00 amRNSNotice of AGM and posting of Annual Report
5th Jun 20237:01 amRNS2022 Annual Results
5th Jun 20237:00 amRNSProposed US pricing for Tutivia™
31st May 20237:00 amRNSNotice of Results
24th May 20237:01 amRNSUpdate re. EKF distribution of shares in Verici Dx
24th May 20237:00 amRNSDistribution of shares in Verici Dx plc
24th Apr 20237:00 amRNSFinal results timing
28th Mar 202311:05 amRNSSecond Price Monitoring Extn
28th Mar 202311:00 amRNSPrice Monitoring Extension
28th Mar 20239:05 amRNSSecond Price Monitoring Extn
28th Mar 20239:00 amRNSPrice Monitoring Extension
27th Mar 20234:35 pmRNSPrice Monitoring Extension
27th Mar 202311:05 amRNSSecond Price Monitoring Extn
27th Mar 202311:00 amRNSPrice Monitoring Extension
22nd Mar 20237:00 amRNSOperational Update

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Make Better Investment Decisions

Register for FREE

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.